Cystic Fibrosis

Top Story

Anthera halts development of EPI drug candidate Sollpura

March 13, 2018
In the Journals Plus

Oral therapy as safe, effective as insulin in cystic fibrosis-related diabetes

December 7, 2017
Patients with cystic fibrosis-related diabetes treated with oral repaglinide for 24 months experienced improvements in HbA1c and pulmonary function that were similar to…
In the Journals

Orkambi yields positive results in younger patients with cystic fibrosis

June 12, 2017
Orkambi improved lung function in patients 6 to 11 years old with cystic fibrosis within 15 days of treatment, according to phase 3 trial results recently published in…
FDA News

FDA expands approval of Kalydeco to include additional cystic fibrosis mutations

May 18, 2017
The FDA has extended approval for ivacaftor to treat 23 additional mutations of cystic fibrosis among pediatric patients aged older than 2 years. Previously, ivacaftor…
More Headlines »
CME Article

Cystic Fibrosis and CRMS Screening: What the Primary Care Pediatrician Should Know

Pediatric Annals, December 2010, Volume 39 Issue 12
“Every physician’s first duty is to diagnose — accurately and promptly.” This mantra is taught…
More »
Meeting News

VIDEO: Pembrolizumab improves overall survival in nonsmall cell lung cancer

May 5, 2017
More »